MedImmune, the R&D arm of AstraZeneca, will make an immediate payment of $10 million to the Israeli cancer immunotherapy company. Israeli cancer immunotherapy company Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN) today announced that it has entered into an exclusive license agreement with MedImmune, the biologics R&D arm of AstraZeneca. The agreement will facilitate the development of bi-specific and multi-specific immuno-oncology antibody products.
{iframe}http://www.globes.co.il/en/article-compugen-signs-cancer-drug-licensing-deal-worth-up-to-200m-1001230238{/iframe}